Neuroprotective evaluation of novel substituted 1,3,4-oxadiazole and aroylhydrazone derivatives. 2022

Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
Laboratory "Drug Metabolism and Drug Toxicity", Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University-Sofia, Bulgaria; Department of Chemistry, Faculty of Pharmacy, Medical University-Sofia, Bulgaria.

The paper reports on the facile and convenient synthesis of a series of novel 2,5-substituted 1,3,4-oxadiazoles 3a-f and that of aroylhydrazone-based molecular hybrids 5a-g from readily available starting materials. The structure of the compounds was confirmed by IR, 1H NMR, 13C NMR and HRESI-MS spectral data. The toxicological potential of the compounds was evaluated by monitoring the synaptosomal viability and the levels of reduced glutathione in rat brain synaptosomes, isolated by Percoll gradient. The neuroprotective effects were assessed in vitro in a model of 6-hydroxydopamine-induced neurotoxicity. Administered alone, at a concentration of 40 µM, most of the 1,3,4-oxadiazole derivatives and all of the hydrazone derivatives exhibited weak statistically significant neurotoxic effects, compared to the control. Two of the compounds from the novel oxadiazoles 3a and 3d did not have any toxicity. In a model of 6-OHDA-induced oxidative stress, again 3a and 3d and all aroylhydrazone derivatives 5a-g revealed statistically significant neuroprotective effect by preserving the synaptosomal viability and the level of reduced glutathione, against the toxic agent. Some of the compounds may have neuroprotective effects due to possible stabilization of the synaptosomal membrane and/or because of the preserved reduced glutathione. Additionally, all the compounds display a good predicted ADME profile.

UI MeSH Term Description Entries
D010069 Oxadiazoles Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. Oxadiazole
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D006835 Hydrazones Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed) Hydrazone
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective

Related Publications

Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
March 2017, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
April 2008, Bioorganic & medicinal chemistry,
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
October 2017, Molecules (Basel, Switzerland),
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
July 2011, Journal of fluorescence,
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
March 2012, Organic and medicinal chemistry letters,
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
April 2024, Molecular diversity,
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
November 2010, European journal of medicinal chemistry,
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
November 2010, European journal of medicinal chemistry,
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
May 2021, Pharmaceuticals (Basel, Switzerland),
Valentin R Karabeliov, and Magdalena S Kondeva-Burdina, and Nikolay G Vassilev, and Elena K-Yovkova, and Violina T Angelova
March 2020, Molecules (Basel, Switzerland),
Copied contents to your clipboard!